Positron emission tomography (PET) is a non-invasive molecular imaging technology constantly expanding, with a high demand for specific antibody-derived imaging probes. The use of tracers based on temperature-sensitive molecules (i.e. Fab, svFab, nanobodies) is increasing and leads us to design a class of chelators based on the structure of 2-aminomethylpiperidine (AMP) with acetic and/or hydroxybenzyl pendant arms (2-AMPTA, NHB-2-AMPDA, and 2-AMPDA-HB), which have been investigated as such for {Al 18 F} 2+ -core chelation efficiency. All the compounds were characterized by HPLC-MS analysis and NMR spectroscopy. The AlF-18 labeling reactions were performed in different conditions (pH/temperature), and the radiolabeled chelates were purified and characterized by radio-TLC and radio-HPLC. The stability of labeled chelates was investigated up to 240min in human serum (HS), EDTA 5mM, PBS and 0.9% NaCl solutions. In vivo stability of [Al 18 F(2-AMPDA-HB)]was assessed in healthy nude mice (n=6). RCYs between 55% and 81% were obtained at pH 5 and rt. High stability in HS was measured for [Al 18 F(2-AMPDA-HB)] -, with 90% of F-18 complexed after 120min. High stability in vivo, a fast hepatobiliary and renal excretion, with irrelevant accumulation of free F-18 in the bones were measured. Thus, this new Al 18 F-chelator may have a great impact on immunoPET radiopharmacy, by facilitating the development of new fluorine-18 labeled heat-sensitive biomolecules.
Introduction
Positron Emission Tomography (PET) is a diagnostic imaging technique based on the use of tracers radiolabeled with positron emitters, among which 11 C, 68 Ga, 18 F, 64 Cu and 89 Zr are the most used in preclinical studies. The choice of β + -emitting radioisotopes for imaging purposes is dictated by several factors such as: the high sensitivity and spatial resolution of PET cameras combined with fast acquisition of data and possibility to acquire dynamic images in tomographic mode [1] ; the availability of biomedical cyclotrons for in-house production of positron emitters and the increasing number of metal-based radiopharmaceuticals, either recently approved by FDA or in late-stage clinical trials. [2] For PET imaging, the selection of the best radionuclide for a given application is the most crucial decision because the physical half-life of the radionuclide must match the expected biological half-life of the radiotracer in vivo. [3] F-18 with t1/2 = 109.8 min, ∼97% β + -emission and a maximum positron energy of 635 keV can be easily produced in high quantities with an on-site cyclotron. Since the half-life of F-18 is long enough to allow multistep labeling reactions, but also short enough to avoid extended irradiation of patients, in the last decades several radiotracers based on F-18 have been developed. [4] Fluorine-18 incorporation into large biomolecules can be achieved by either a direct or an indirect labeling approach. Typically, the direct preparation of [ 18 F]radiotracers involved the attachment of 18 F to a carbon in the organic structure of the radiotracer, often requiring a base and high temperatures. Although there are few example of direct fluorine-18 labeling of peptides, protein labeling is typically performed using indirect labeling methods. [5] [6] [7] In this approach, a small molecule containing a suitable functional group is radiolabeled by conventional nucleophilic substitution chemistry using [ 18 F]fluorine and then conjugated to the proteins of interest. The most widely used prosthetic group is N-succinimidyl-4-[ 18 F]fluorobenzoate ([ 18 F]SFB) for conjugation to amine functionalities [8] [9] [10] [11] and 18 F-N- [2] (4-Fluorobenzamido)ethyl]maleimide ([ 18 F]FBEM) for conjugation to thiols on cysteine residues [12] [13] [14] . However, while each of these methods has certain advantages, other complications have limited their applications for clinical purposes. Therefore, the requirement of faster labeling methods boosted the search of new strategies based on the fluoride anion complexation/coordination chemistry and thus, the formation of an 18 F-group-13 element bond, i.e. boron, aluminum and gallium. [15] Among these methods, the complexation of {Al 18 F} 2+ with an appropriate chelator is one of the most studied, and it shows great potential. [16] , [17] In fact, the aluminum-fluoride bond is stronger than 60 other metal-fluoride bonds (bond energy of 670 kJ/mol) [18] ,and it is very stable in vivo, making small amounts of aluminum fluoride chelate compatible with biological systems [19] . In this method, 18 Finteracts with Al 3+ to form {Al 18 F} 2+ (fluoranylaluminum(2+)) which can be chelated by a suitable polydentate ligand. If the chelating agent is modified to contain a chemically reactive functional group for conjugation to biomolecules, it is possible to carry out a direct labeling. [20] Aluminum(III) forms octahedral complexes, therefore a pentadentate chelator is preferable, as it leaves only a binding site available for 18 F -. McBride et al. were the first to explore the Al-18 F method in 2009 with the 1,4,7-triazacyclononane-1,4,7triacetate (NOTA) [16] chelator. Then, in 2011 both McBride and Shetty identified the pentadentate 1,4,7-triazacyclononane-1,4diacetate (NODA) chelator as the best among those tested [21] [22] [23] .
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It has been shown that the most stable Al III complexes are based on multidentate ligands with two neutral N-amines and three negatively charged O-carboxylic or phenolic donor atoms (N2O3), providing the ideal coordination sphere for {Al 18 F} 2+ . In case of NODA-derivatives conjugated peptides, a kit which contains Al III , a radioprotector (ascorbic acid), a non-volatile buffer (potassium bis-phthalate) and a stabilizing agent (trealose) has also been developed [24] . Although these macrocyclic chelators show considerable potential, the high temperature required for the complexation reaction (≥ 100°C) [25] [26] [27] represents a limit to the widespread application of this radiolabeling approach, especially in the presence of thermosensitive biomolecules such as proteins, Fab fragments (55 kDa), scFab (28 kDa) or nanobodies (15kDa). Starting from 2016, Cleeren et al. developed new classes of chelators [28, 29] that can be used to perform radiofluorination at moderate temperature (<40°C) using the McBride modified protocol [30] . They have developed a number of N2O3 pentadentate ligands based on ethylenediamine and 1,2cyclohexanediamine having three acetate pendant arms (in case of ethylenediamine based ligands, also hydroxybenzyl arms were used). The RESCA chelator was conjugated to a series of biomolecules such as HSA, a nanobody targeting the Kupffer cell marker CRIg and an affibody targeting HER2 and labeled with Al 18 F. [29] It is well-known that, to increase the kinetic inertness of a metal complex, it is important to increase the rigidity of the chelator and the pre-organization of the ligand. [31, 32] However, at the same time, it is necessary to maintain a linear and nonmacrocyclic structure of the polydentate chelator to allow a fast complexation kinetics and avoid the need to work at high temperatures, not compatible with some biomolecules. Therefore, the ideal structure of the pentadentate chelator should have an intrinsic rigidity provided by a cycloalkane or a heterocycle, and then flexible pendant arms. In the light of this, we designed a new class of chelators (see Scheme 1) based on the structure of 2-aminomethylpiperidine (AMP) with acetic and/or hydroxybenzyl pendant arms (2-AMPTA, NHB-2-AMPDA and 2-AMPDA-HB) and we tested their {Al 18 F} 2+ labeling efficiency and stability in physiological conditions. Moreover, we investigated the in vivo stability and biodistribution of the [Al 18 F(2-AMPDA-HB)]compound, that has shown the best performance during in vitro studies. Scheme 1. AMP-based chelators discussed in this work.
Results and Discussion
Synthesis. The chelators 2-AMPTA and 2-AMPDA-HB were synthesized starting from racemic 2-aminomethylpiperidine, whereas NHB-2-AMPDA was obtained starting from racemic Boc-protected 2-AMP, as shown in Scheme 2. The main difference between the three ligands is the relative position of the acetic and hydroxybenzyl arms. Briefly, the triacetic derivative 2-AMPTA was obtained in overall 61% yield by nucleophilic substitution by the amines of 2-AMP on tert-butyl bromoacetate followed by deprotection of the carboxylic acids with TFA in DCM. In case of 2-AMPDA-HB, the reductive amination between the primary amine of 2-AMP and salicylaldehyde was followed by the alkylation of the secondary amines with tert-butyl bromoacetate and subsequent deprotection of the acid moieties. The synthesis of NHB-2-AMPDA started with the reaction of 2-chloromethyl-4-nitrophenol on the piperidine nitrogen: this step introduced a 4-nitro-2hydroxybenzyl pendant arm that characterizes this chelator. Then, after removal of the Boc protecting group with TFA/DCM, two tert-butyl acetate arms were introduced on the 2aminomethyl group and, finally, the carboxylates were deprotected. Al 19 F-complexes were also prepared following a reported procedure, in order to characterize the cold Al 19 Fcomplexes. [28] AMP-ligands and Al 19 F-complexes were purified by semi-preparative HPLC-MS (Figures S1-S2) and characterized by ESI MS and 1 H, 19 
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and one at -165 ppm. The presence of more than one 19 F NMR resonance in case of the two phenol-functionalized derivatives is probably due to different positions occupied by the fluoride ion in the octahedral coordination geometry of the Al III ion ( Figure S9 ), as already reported previously for other AlF-complexes. [28, 33] Notably, the acquisition of the 19 F NMR spectra after two months did not show significant differences proving a good stability of the complexes in water at pH 7 ( Figure S10 ). In addition, 19 F NMR spectra of [Al 19 F(NHB-2-AMPDA)]acquired at different temperatures (283-353 K, Figure S10 ) showed an equilibrium between the coordination isomers as the integral ratio between the signals changes with temperature.
Radiolabeling experiments. The preparation of {Al 18 F} 2+ and the subsequent labeling with AMP-based chelators were carried out by slight modification of the procedure reported by Bormans and colleagues. [28] In particular, labeling reactions were performed at pH 4 and 5 and at three different temperatures for each pH value (room temperature, 37 °C and 80 °C) for 12 min. RCYs were calculated by radio-TLC analysis. All the radiolabeled complexes were purified using a Sep-Pak Plus Alumina-N-cartridges (Waters), following a previously reported protocol [30] and characterized via radio-HPLC ( Figure S11 ). At pH 4, only 2-AMPTA chelator is able to efficiently complex {Al 18 F} 2+ with a RCY between 77% and 86% ( Figure 1a ). This is consistent with the presence of the acetic pendant arms, which are more acidic compared to the phenol groups that are protonated at pH 4. At this pH, only heating the reaction to 80 °C we obtain a good RCY for the other two chelators. On the other hand, at pH 5 all three chelators were successfully labeled, and a RCY between 55 and 81% was obtained at room temperature (55% 2-AMPDA-HB, 69% NHB-2-AMPDA and 81% 2-AMPTA, respectively). Increasing the temperature to 37 and 80 °C allowed improving the RCY for 2-AMPDA-HB for which the radiolabeling efficiency reached 75%. Comparing the labeling results for the three chelators, we can conclude that, as already reported previously on for similar pentadentate N2O3 ligands [28] , the most acidic ligand 2-AMPTA, with three carboxylic acids and without a phenol moiety, is more reactive than the ligands containing a phenolate moiety as donor. In fact, phenols in acidic conditions (pH 4) are almost fully protonated, and for this reason less available to chelate {Al 18 F} 2+ ions. Since a pronounced pH dependence was observed for the labeling reaction of AMP-based chelators with {Al 18 F} 2+ , a more detailed study to assess the labeling efficiency at rt versus pH was performed ( Figure 2 ). The pH value and reaction buffer are really important for the radiofluorinations using {Al 18 F} 2+ , because at pH<4 fluorine is present in solution also in the HF form, while at pH>5 Al III it starts to form hydroxide species [34] . In both cases
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the species compete with the formation of {Al 18 F} 2+ and, therefore, influence the RCYs. As shown in Figure 2 , the three chelators are able to complex {Al 18 F} 2+ with good yield also at higher pH, with a RCY around 50% at pH 6.5. Notably, the ability to form the labeled complex at almost neutral pH is important and can have an impact on the labeling of acid sensitive biomolecules. The different behavior of the three chelators again reflects the different acidity of the donor groups: for 2-AMPTA the higher RCY was measured at pH 4.5, whereas for NHB-2-AMPDA at pH 5 and up to pH 6 in case of 2-AMPDA-HB, which presents an un-substituted, weaker acid, phenol group. Figure 1b we also performed a parallel labeling experiment on the p-SCN-Bn-NOTA chelator at pH 5 using the same labeling conditions reported for the AMP-based chelators. As expected, the NOTA derivative was not able to form a stable complex with {Al 18 F} 2+ at the tested temperatures (room temperature, 37°C and 80°C) and the RCYs were respectively 0.96% (±0.11), 3.72% (±0.35), 25 .3% (±1.74). From this comparison, we can then confirm that the new AMP-based chelators have better labeling performance at low temperature compared to p-SCN-Bn-NOTA.
Head-to-head labeling comparison of 2-AMPDA-HB vs p-SCN-Bn-NOTA chelator. As shown in
In vitro stability studies. Stability studies were performed on purified products after radiofluorination at pH 5 and room temperature ( Table 1 ). The {Al 18 F} 2+ complexes were incubated at 37 °C for 240 minutes in Human Serum (HS), PBS, EDTA 5 mM (1000-fold excess) and NaCl 0.9% solutions respectively, and the percentage of 18 Fcoordinated to the Al III -complex measured via radio-TLC analysis. Excellent stability in HS was measured for [Al 18 F(2-AMPDA-HB)]with a 90±4% of intact complex after 120 min, higher if compared to other reported ligands [28] . On the other hand, for [Al 18 F(2-AMPTA)]and [Al 18 F(NHB-2-AMPDA)]complexes, 55±9% and 46±4% of coordinated 18 Fwas measured. Measuring the percentage of coordinated 18 Fup to 4 h, a remarkable stability in HS was found for the labeled [Al 18 F(2-AMPDA-HB)] -(87 ± 5%), and great stability also in PBS, EDTA 5 mM and NaCl 0.9%, about 90% after 4 h. The stability study on the labeled complexes shows that [Al 18 F(2-AMPDA-HB)]is substantially more stable than the other chelates. This trend is not the same as that found for RCYs where 2-AMPTA resulted the most reactive among the three chelators. A possible explanation is a higher flexibility of the acetate arms in 2-AMPTA that allows a faster and more efficient complexation, but at the same time a lower stability already after 30 min. Conversely, a higher rigidity provided by the phenol pendant in 2-AMPDA-HB leads to lower RCYs, but at the same time to a higher stability towards dissociation of the complex in physiological conditions. Based on stability results, the theoretical higher specific activity of the most stable compound, [Al 18 F(2-AMPDA-HB)] -, was calculated to be 32 GBq/µmol. 
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In vivo studies. Due to the high in vitro stability measured for [Al 18 F(2-AMPDA-HB)]in HS, we decided to test its stability in vivo. Such experiments were performed by injecting healthy female nude mice (n=6) with 2.3±0.1 MBq of [Al 18 F(2-AMPDA-HB)]and performing dynamic PET/CT scans for up to 90 minutes. Afterwards, mice were sacrificed 2h p.i. to perform a biodistribution analysis. In Figure 3 , PET-CT images are reported as frames of the dynamic scan extracted at different time points using the Inveon Research Workplace software (Siemens, Knoxville, TN). [Al 18 F(2-AMPDA-HB)]complex presented fast blood clearance, hepatobiliary and renal excretion, as expected due to the Log P value of -2.47±0.4 and the low molecular weight of the compound [35] . Performing image-derived uptake calculation on dynamic PET-CT scans by drawing region of interest (ROIs) on selected organs, we were also able to study the biodistribution of the tracer over the time analysis as shown in Figure S12 . A fast blood clearance (heart ROI) and kidney elimination was measured over time, and also a fast hepatobiliary clearance was confirmed.
Ex vivo studies. Based on biodistribution results (Figure 4 and Table S1 ) and according to the dynamic PET-CT ROI calculations, we can confirm that the labeled complex [Al 18 F(2-AMPDA-HB)]shows high stability in vivo as shown by the irrelevant amount of 18 F accumulation measured in femur (%ID/g: 1.63±0.73%) and other organs at 2 h p.i.. Since the aluminum-fluoride bond is very strong (670 kJ/mol), [18] the activity accumulated in the organs cannot be ascribed to 18 Freleased from the Al III chelate, but either to the intact complex or Al 18 F dissociated from the ligand. These results are really promising when compared to other in vivo studies reported in literature [28] showing an accumulation in bones of free {Al 18 F} 2+ equal to 83% ID ± 10.65 and {Al 18 F} 2+ -ligands of 2.5% ID ± 0.64 60 min p.i. [28] In fact, radio-TLC analysis of mice's urine performed 2 h p.i. showed that the 68±0.1% of activity was still present as [Al 18 F(2-AMPDA-HB)]complex (data not shown). According with PET images, our biodistribution data confirm the fast hepatobiliary/renal excretion of the labeled chelate due to the low molecular weight of 381 Da [35] and the mild lipophilicity (log P=-2.47±0.4). A similar behavior was also obtained in previous works based on AlF-18 compounds non conjugated to a biomolecule, which are then in agreement with our results. [23] , [28] Although, a "naked" and negatively charged Al 18 Fchelate complex does not persist in vivo long enough to encounter challenge to its structural integrity compared to a conjugated version, nevertheless the results obtained speech for a stable Al 18 F-complex once conjugated with a biomolecule. The accumulation measured at 10 minutes p.i. in the liver ( Figure  S12 ) is due to the excretion pathway of the labeled chelator, which only transits through the organ and does not residualize into it. As already reported above, the chelator will be conjugated to vector molecules having specific binding capacity for tumor-associated targets. Therefore, we expect a different biodistribution of the labeled complex dictated by the pharmacokinetic characteristic of the vector molecules. 10 .1002/cmdc.201900652
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Conclusions
Three pentadentate ligands based on the structure of 2aminomethylpiperidine and having acetate and/or hydroxybenzyl pendant arms were synthesized and complexed with Al 19 F. The labeling with Al 18 F was carried out at different temperatures and pH, finding the optimal labeling conditions for each chelator. In general, a very good radiochemical yield was obtained for all chelators at pH 5 and 25°C. The stability tests on the radiolabeled complexes showed that the Al 18 F complex with 2-AMPDA-HB is the most stable in all conditions, presenting 90% of 18 F complexed up to 240 min. With this Al 18 F tracer an in vivo study was performed on nude mice and a good stability, a very low amount of 18 F accumulation in bones and a fast renal excretion were measured. The promising results obtained in this work prompted us towards the synthesis of a bifunctional derivative of 2-AMPDA-HB that will allow the conjugation with temperature-sensitive biomolecules, e.g. Fab fragments and/or nanobodies, the labeling at room temperature and then in vivo applications.
Experimental Section
General. All chemicals were purchased from commercial sources and were used without purification. Water was purified (18 MΩ cm) using a standard Milli-Q system (Millipore, Bedford, MA, USA). Elemental analyses were carried out with a EA3000 CHN Elemental Analyzer (EuroVector, Milano, Italy). NMR spectra (including 1 H-decoupled 13 C NMR) were recorded on a Bruker Avance III spectrometer operating at 11.74 T, corresponding to a protonic resonance frequency of 499.8 MHz. 1 H and 13 C NMR chemical shifts are reported relative to TMS and are referenced using the residual proton solvent resonances. 19 F NMR chemical shifts are reported relative to CFCl3. Samples were prepared in 5 mm NMR tubes by dissolving the compounds in appropriate deuterated solvents. Splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), double doublet (dd), triplet (t), multiplet (m) or broad multiplet (bm). ESI mass spectra were recorded on a Waters SQD 3100. Analytical HPLC-MS were carried out on Waters modular system equipped with Waters 1525 binary pump, Waters 2487 UV/Vis and Waters SQD 3100 (ESCI ionization mode) detectors, using an XBridge TM Phenyl 3.5 µm 4.6x150 mm column (Waters). Semi-preparative HPLC purifications were performed with an XBridge TM Prep Phenyl 5 µm OBD TM 19x100 mm column (Waters). The HPLC methods are indicated for each procedure and reported in the Supporting Information (SI). Knoxville, TN) . The activity accumulation in specific organs was measured in ex vivo experiments using a γ-counter (Perkin Elmer).
Synthesis of 2-AMPTA.
tert-Butyl 2-aminomethylpiperidine triacetate (AMPTA(OtBu)3).
2-Aminomethylpiperidine (1 mL, 8.24 mmol) was dissolved in MeCN (50 mL). K2CO3 (5.12 g, 37.04 mmol) was added, followed by tert-butyl bromoacetate (4.0 mL, 27.2 mmol), and the mixture was stirred at reflux overnight. The solvent was evaporated under reduced pressure, the residue was suspended in EtOAC (100 mL) and washed with H2O (50 mL) and brine (2x50 mL). The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude product was purified by flash chromatography (SiO2, PetEt/EtOAC 90:10 80:20, Rf 90:10 = 0.22), leading to the aimed compound as a yellow-colored oil (2.50 g, 66.4%). 1 2-AMPTA. AMPTA(OtBu)3 (0.31 g, 0.69 mmol) was dissolved in DCM (5 mL). TFA (5 mL) was added and the mixture was stirred at room temperature for 6 h. The solvents were evaporated under reduced pressure and the residue was redissolved in TFA (1 mL) and precipitated in Et2O (10 mL). The suspension was centrifuged (4000 rpm, 15 min, 10 °C) and the precipitate was washed/centrifuged with Et2O (3x10 mL). The product was purified by preparative HPLC-MS (Method P1, tR = 5.2 min), and it was obtained as mono-trifluoroacetate salt after lyophilization (184 mg, 66% Synthesis of NHB-2-AMPDA.
2-(Boc-aminomethyl)-N-(2-hydroxy-4-nitrophenylmethyl)piperidine.
2-(Boc-aminomethyl)piperidine (322 mg, 1.50 mmol) was dissolved in DMF (10 mL). K2CO3 (415 mg, 3.00 mmol) was added, followed by 2chloromethyl-4-nitrophenol (563 mg, 3.00 mmol), and the mixture was stirred at reflux overnight. The solvent was evaporated under reduced pressure, the residue was suspended in EtOAC (40 mL) and washed with H2O (2x50 mL) and brine (50 mL). The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude product was purified by flash chromatography (SiO2, cyclohexane/acetone 95:5 80:20, Rf 90:10 = 0.34), leading to the aimed compound as a yellow solid (262 mg, 48%). 1 
2-Aminomethyl-N-(2-hydroxy-4-nitrophenylmethyl)piperidine.
2-(Boc-aminomethyl)-N-(2-hydroxy-4-nitrophenylmethyl)piperidine (235 mg, 0.64 mmol) was dissolved in DCM (5 mL). TFA (5 mL) was added and the mixture was stirred at room temperature for 3 h. The solvents were evaporated under reduced pressure and the residue was redissolved in TFA (1 mL) and precipitated in Et2O (10 mL). The suspension was centrifuged (4000 rpm, 15 min, 10 °C) and the precipitate was washed/centrifuged with Et2O (3x10 mL). The product was obtained in the trifluoroacetate form as a yellow solid (216 mg, 89%). 1 
tert-Butyl 2-aminomethyl-N-(2-hydroxy-4nitrophenylmethyl)piperidine diacetate (NHB-2-AMPDA(OtBu)2). 2-
Aminomethyl-N-(2-hydroxy-4-nitrophenylmethyl)piperidine (216 mg, 0.57 mmol) was dissolved in DMF (2 mL). K2CO3 (157 mg, 1.14 mmol) was added, followed by tert-butyl bromoacetate (0.167 mL, 1.14 mmol), and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, the residue was suspended in EtOAC (10 mL) and washed with H2O (2x5 mL) and brine (5 mL 
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1H, NCHCH2CH2). 1.42 (s, 18H, CH3). 13 NHB-2-AMPDA. NHB-2-AMPDA(OtBu)2 (27 mg, 0.055 mmol) was dissolved in DCM (1 mL). Triisopropylsylane (1 drop) was added, followed by TFA (1 mL), and the mixture was stirred at room temperature for 15 h. The solvents were evaporated under reduced pressure, the residue was dissolved in TFA (1 mL) and precipitated in Et2O (10 mL). The suspension was centrifuged (4000 rpm, 15 min, 10 °C) and the precipitate was washed/centrifuged with Et2O (3x10 mL) and dried under vacuum. The residue was redissolved in concentrated HCl (5 mL) and stirred at ambient temperature for 30 min. After lyophilization, the product was obtained as mono-hydrochloride salt ( Synthesis of 2-AMPDA-HB.
2-(N-(2-Hydroxybenzyl)aminomethyl)piperidine.
(DL)-2aminomethylpiperidine (0.50 mL, 4.12 mmol) was dissolved in dry MeOH (10 mL). At 0 °C, AcOH (1 drop) was added, followed by salicylaldehyde (0.48 mL, 4.53 mmol), and the resulting yellow mixture was stirred at room temperature for 2 h. NaBH4 (850 mg, 22.47 mmol) was then added portionwise at 0 °C, and the suspension was stirred at room temperature for further 15 h. H2O (3 mL) was added and stirring was continued at room temperature for 30 min. The volatiles were evaporated under reduced pressure, and the residue was suspended in EtOH (10 mL) and filtered through a PTFE membrane. The solvent was evaporated and the crude product (1.00 g) was used as such without further purification. ESI + MS: m/z 221.1 [M+H + ], calc. for [C13H21N2O] + = 221.32 g/mol. Butyl 2-(N-(2-hydroxybenzyl) aminomethyl)piperidine diacetate (2-AMPDA-HB(OtBu)2). 2-(N-(2-Hydroxybenzyl)aminomethyl)piperidine (1.00 g, 4.54 mmol, theoretical) was dissolved in MeCN (50 mL). K2CO3 (2.51 g, 18.16 mmol) was added, followed by tert-butyl bromoacetate (2.00 mL, 13.64 mmol), and the mixture was heated to reflux and stirred overnight. The solvent was evaporated under reduced pressure, the residue was suspended in EtOAc (50 mL) and washed with H2O (2x25 mL) and brine (25 mL). The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude product was purified by flash chromatography (SiO2, PetEt/EtOAc 80:20 70:30, Rf 80:20 = 0.24), leading to the aimed compound as a colorless oil (855 mg, 42%). 1 2-AMPDA-HB. 2-AMPDA-HB(OtBu)2 (200 mg, 0.44 mmol) was dissolved in DCM (3 mL). Triisopropylsylane (1 drop) was added, followed by TFA (3 mL), and the mixture was stirred at room temperature for 15 h. The solvents were evaporated under reduced pressure and the residue was redissolved in TFA (1 mL) and precipitated in Et2O (10 mL). The suspension was centrifuged (4000 rpm, 15 min, 10 °C) and the precipitate was washed/centrifuged with Et2O (3x10 mL) and dried under vacuum. The product was purified by preparative HPLC-MS (Method P2, tR = 5.6 min), and the product was obtained after lyophilization as monotrifluoroacetate salt (38 mg, 19%). HPLC-MS (Method A2): tR = 9.6 min. Elemental analysis: found C, 50.59; H, 5.59; N, 6.19; calc. for C19H25F3N2O7 C, 50.67; H, 5.59; N, 6.22. 1 
tert-
